Molecular Partners AG (MOLN)
NASDAQ: MOLN · IEX Real-Time Price · USD
3.700
+0.060 (1.65%)
Apr 29, 2024, 3:56 PM EDT - Market closed
Molecular Partners AG Revenue
In the year 2023, Molecular Partners AG had annual revenue of $8.38M, a decrease of -95.89%. Revenue in the quarter ending December 31, 2023 was $1.23M, a -57.62% decrease year-over-year.
Revenue (ttm)
$8.38M
Revenue Growth
-95.89%
P/S Ratio
14.51
Revenue / Employee
$50,171
Employees
167
Market Cap
121.56M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.38M | -195.49M | -95.89% |
Dec 31, 2022 | 203.87M | 193.15M | 1,802.02% |
Dec 31, 2021 | 10.72M | 100.50K | 0.95% |
Dec 31, 2020 | 10.62M | -10.40M | -49.47% |
Dec 31, 2019 | 21.01M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
So-Young International | 211.29M |
Seres Therapeutics | 126.33M |
Zomedica | 25.19M |
Seer, Inc. | 16.66M |
Vaxart | 7.38M |
Omega Therapeutics | 3.09M |
Delcath Systems | 2.07M |
Sagimet Biosciences | 2.00M |
MOLN News
- 17 hours ago - Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action - GlobeNewsWire
- 10 days ago - Life Science Cares Launches in Switzerland - GlobeNewsWire
- 12 days ago - Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting - GlobeNewsWire
- 4 weeks ago - Molecular Partners Publishes Invitation to Annual General Meeting 2024 - GlobeNewsWire
- 6 weeks ago - Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 - GlobeNewsWire
- 2 months ago - Molecular Partners Announces Dismissal of Class Action Lawsuit - GlobeNewsWire
- 2 months ago - Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations - GlobeNewsWire
- 4 months ago - Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire